{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T01:05:05Z","timestamp":1768525505135,"version":"3.49.0"},"posted":{"date-parts":[[2025,10,9]]},"group-title":"Microbiology","reference-count":84,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,10,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                <jats:p>\n                  Epstein-Barr virus (EBV) is associated with multiple malignancies including Burkitt lymphoma (BL), Hodgkin\u2019s lymphomas, nasopharyngeal carcinomas (NPC), and gastric cancers. Canonically, EBV positive tumors display latent gene expression programs that are difficult to target pharmacologically. To overcome this hurdle, lytic reactivation therapies have been developed based on HDAC inhibition with limited mechanistic studies. We therefore characterized the impact of pan-HDAC inhibitor, panobinostat, and class I HDAC inhibitor, nanatinostat, on the growth, survival, and lytic reactivation of four EBV-positive cell lines: P3HR1-ZHT BL, Jijoye BL, IBL-1 immunoblastic lymphoma, and\n                  <jats:italic>de novo<\/jats:italic>\n                  infection derived lymphoblastoid cell lines (LCL). All lines were sensitive, enabling us to define ranges of sensitivity within which to use single cell approaches to assess early EBV lytic gene expression, cell cycle state, and apoptosis. We observed that each EBV-positive model of malignancy responded uniquely to the same HDAC inhibitors and that lytic reactivation was successful in only a small percentage of the cell population. To elucidate the potential role of host factors in preventing successful lytic reactivation, we performed single-cell RNA sequencing on the P3HR1-ZHT BL line treated with the HDAC inhibitor panobinostat. We observed that abortive lytic cells, or cells that do not successfully progress through the lytic cycle, upregulated genes downstream of NF-\u03baB activity. Additionally, genes involved in immune signaling including the CD137\/CD137L signaling axis, were upregulated in abortive lytic cells. These data have important implications for how we approach oncolytic therapies for EBV-associated malignancies.\n                <\/jats:p>\n                <jats:sec>\n                  <jats:title>AUTHOR SUMMARY<\/jats:title>\n                  <jats:p>Epstein-Barr virus (EBV) is an extremely prevalent human herpesvirus that is associated with a variety of cancers and autoimmune diseases. EBV establishes latent infection in the host and, under various circumstances, can reactivate the lytic cycle to produce more infectious particles. In the context of EBV-associated malignancies, the virus is most often maintained in a latent state, which makes it difficult to target with pharmaceuticals. To develop more viral targeted strategies, kick and kill regiments have been investigated. This therapy involves reactivating the virus with an HDAC inhibitor followed by treatment with an antiviral drug. It is well established that reactivating EBV with pharmaceuticals is often inefficient and leads to heterogeneous responses, including an abortive lytic trajectory. To better characterize the overall effect of two classes of HDAC inhibitors in various models of EBV-associated malignancies, we utilized single-cell techniques to capture various responses to stimuli. Consistent with prior studies, HDAC inhibition led to both successful and abortive lytic populations. Single-cell RNA sequencing provided evidence of upregulated immune signaling pathways in this abortive lytic population. This study provides in depth characterization of lytic reactivation with a biologically relevant stimulus.<\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2025.10.09.681362","type":"posted-content","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T02:50:10Z","timestamp":1760064610000},"source":"Crossref","is-referenced-by-count":0,"title":["Single-Cell Profiling of HDAC Inhibitor-Induced EBV Lytic Heterogeneity Defines Abortive and Refractory States in B Lymphoblasts"],"prefix":"10.64898","author":[{"given":"Lauren E.","family":"Haynes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley P.","family":"Barry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2964-1907","authenticated-orcid":false,"given":"Micah A.","family":"Luftig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2025101313401020000_2025.10.09.681362v1.1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-037505"},{"key":"2025101313401020000_2025.10.09.681362v1.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80622-6"},{"issue":"6","key":"2025101313401020000_2025.10.09.681362v1.3","doi-asserted-by":"crossref","first-page":"e0199398","DOI":"10.1371\/journal.pone.0199398","article-title":"Clinical characteristics and prognostic significance of EBER positivity in diffuse large B-cell lymphoma: A meta-analysis","volume":"13","year":"2018","journal-title":"PLoS One"},{"key":"2025101313401020000_2025.10.09.681362v1.4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00713"},{"key":"2025101313401020000_2025.10.09.681362v1.5","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.2.1296-1307.2005"},{"key":"2025101313401020000_2025.10.09.681362v1.6","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910350107"},{"key":"2025101313401020000_2025.10.09.681362v1.7","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1182\/blood-2019-132004","article-title":"Combination of Oral Nanatinostat (Nstat), a Novel Histone Deacetylase Inhibitor (HDACi), and the Oral Anti-Viral, Valganciclovir (VGCV), Is Active in Relapsed\/Refractory (R\/R) Epstein-Barr Virus (EBV)-Positive B-Cell, T-Cell, and Hodgkin Lymphoma: Interim Safety and Efficacy Results from a Phase 1b\/2a Study","volume":"134","year":"2019","journal-title":"Blood"},{"key":"2025101313401020000_2025.10.09.681362v1.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2006.10.008"},{"key":"2025101313401020000_2025.10.09.681362v1.9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-362434"},{"issue":"2","key":"2025101313401020000_2025.10.09.681362v1.10","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1006\/bcmd.1998.0178","article-title":"Arginine Butyrate-Induced Susceptibility to Ganciclovir in an Epstein\u2013Barr-Virus-Associated Lymphoma. Blood Cells","volume":"24","year":"1998","journal-title":"Molecules, and Diseases"},{"key":"2025101313401020000_2025.10.09.681362v1.11","doi-asserted-by":"publisher","DOI":"10.1021\/cb4006326"},{"key":"2025101313401020000_2025.10.09.681362v1.12","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29698"},{"key":"2025101313401020000_2025.10.09.681362v1.13","first-page":"55","article-title":"Woodward Award: development of novel, EBV-targeted therapies for EBV-positive tumors","volume":"117","year":"2006","journal-title":"Trans Am Clin Climatol Assoc"},{"issue":"20","key":"2025101313401020000_2025.10.09.681362v1.14","first-page":"5781","article-title":"Activation of Lytic Epstein-Barr Virus (EBV) Infection by Radiation and Sodium Butyrate in Vitro and in Vivo: A Potential Method for Treating EBV-positive Malignancies1","volume":"60","year":"2000","journal-title":"Cancer Research"},{"key":"2025101313401020000_2025.10.09.681362v1.15","doi-asserted-by":"crossref","unstructured":"Hui, K.F. , et al., Viral-Targeted Strategies Against EBV-Associated Lymphoproliferative Diseases. Frontiers in Oncology, 2019. 9(81).","DOI":"10.3389\/fonc.2019.00081"},{"key":"2025101313401020000_2025.10.09.681362v1.16","doi-asserted-by":"crossref","unstructured":"Yiu, S.P.T. , et al., Lytic Induction Therapy against Epstein-Barr Virus-Associated Malignancies: Past, Present, and Future. Cancers (Basel), 2020. 12(8).","DOI":"10.3390\/cancers12082142"},{"key":"2025101313401020000_2025.10.09.681362v1.17","doi-asserted-by":"crossref","unstructured":"Eckschlager, T. , et al., Histone Deacetylase Inhibitors as Anticancer Drugs. Int J Mol Sci, 2017. 18(7).","DOI":"10.3390\/ijms18071414"},{"key":"2025101313401020000_2025.10.09.681362v1.18","doi-asserted-by":"publisher","DOI":"10.3390\/molecules20033898"},{"key":"2025101313401020000_2025.10.09.681362v1.19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-312603"},{"key":"2025101313401020000_2025.10.09.681362v1.20","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a018713"},{"key":"2025101313401020000_2025.10.09.681362v1.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2010.01.042"},{"key":"2025101313401020000_2025.10.09.681362v1.22","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210620"},{"key":"2025101313401020000_2025.10.09.681362v1.23","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-014-1656-6"},{"key":"2025101313401020000_2025.10.09.681362v1.24","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1013754107"},{"key":"2025101313401020000_2025.10.09.681362v1.25","doi-asserted-by":"publisher","DOI":"10.2174\/092986712802884286"},{"key":"2025101313401020000_2025.10.09.681362v1.26","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010330"},{"key":"2025101313401020000_2025.10.09.681362v1.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2014.01.002"},{"key":"2025101313401020000_2025.10.09.681362v1.28","doi-asserted-by":"crossref","unstructured":"Kenney, S.C. , Reactivation and lytic replication of EBV, in Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis, C.-F.G. Arvin A, Mocarski E, et al., Editor. 2007, Cambridge University Press: Cambridge.","DOI":"10.1017\/CBO9780511545313.026"},{"key":"2025101313401020000_2025.10.09.681362v1.29","doi-asserted-by":"publisher","DOI":"10.1016\/0042-6822(91)90778-A"},{"key":"2025101313401020000_2025.10.09.681362v1.30","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.20.10282-10289.2002"},{"key":"2025101313401020000_2025.10.09.681362v1.31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005718"},{"key":"2025101313401020000_2025.10.09.681362v1.32","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02139-14"},{"key":"2025101313401020000_2025.10.09.681362v1.33","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00159-12"},{"key":"2025101313401020000_2025.10.09.681362v1.34","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.7.2082-2091.2001"},{"key":"2025101313401020000_2025.10.09.681362v1.35","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-66-9-1931"},{"key":"2025101313401020000_2025.10.09.681362v1.36","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.74.2.710-720.2000"},{"key":"2025101313401020000_2025.10.09.681362v1.37","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01602-10"},{"key":"2025101313401020000_2025.10.09.681362v1.38","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.83533-0"},{"issue":"2","key":"2025101313401020000_2025.10.09.681362v1.39","first-page":"e01894","article-title":"Reactivation of Epstein-Barr Virus from Latency Involves Increased RNA Polymerase Activity at CTCF Binding Sites on the Viral Genome","volume":"97","year":"2023","journal-title":"Journal of Virology"},{"key":"2025101313401020000_2025.10.09.681362v1.40","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.1.5.1045-1051.1967"},{"issue":"1","key":"2025101313401020000_2025.10.09.681362v1.41","first-page":"623","article-title":"Nanatinostat (Nstat) and Valganciclovir (VGCV) in Relapsed\/Refractory (R\/R) Epstein-Barr Virus-Positive (EBV +) Lymphomas: Final Results from the Phase 1b\/2 VT3996-201 Study","volume":"138","year":"2021","journal-title":"Blood"},{"key":"2025101313401020000_2025.10.09.681362v1.42","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00116-08"},{"issue":"10","key":"2025101313401020000_2025.10.09.681362v1.43","doi-asserted-by":"crossref","first-page":"e1012341","DOI":"10.1371\/journal.ppat.1012341","article-title":"Epstein-Barr virus reactivation induces divergent abortive, reprogrammed, and host shutoff states by lytic progression","volume":"20","year":"2024","journal-title":"PLOS Pathogens"},{"key":"2025101313401020000_2025.10.09.681362v1.44","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00382-09"},{"issue":"1","key":"2025101313401020000_2025.10.09.681362v1.45","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41467-021-27729-z","article-title":"Zero-preserving imputation of single-cell RNA-seq data","volume":"13","year":"2022","journal-title":"Nature Communications"},{"issue":"1","key":"2025101313401020000_2025.10.09.681362v1.46","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/s41467-021-21246-9","article-title":"Inference and analysis of cell-cell communication using CellChat","volume":"12","year":"2021","journal-title":"Nature Communications"},{"issue":"3","key":"2025101313401020000_2025.10.09.681362v1.47","first-page":"549","article-title":"The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-kappa B and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain","volume":"10","year":"1995","journal-title":"Oncogene"},{"key":"2025101313401020000_2025.10.09.681362v1.48","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.19.9150"},{"key":"2025101313401020000_2025.10.09.681362v1.49","doi-asserted-by":"publisher","DOI":"10.1016\/J.MOLCEL.2020.03.025"},{"key":"2025101313401020000_2025.10.09.681362v1.50","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01745-09"},{"key":"2025101313401020000_2025.10.09.681362v1.51","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00121-15"},{"key":"2025101313401020000_2025.10.09.681362v1.52","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.2001.6067"},{"key":"2025101313401020000_2025.10.09.681362v1.53","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830231037"},{"issue":"3","key":"2025101313401020000_2025.10.09.681362v1.54","doi-asserted-by":"crossref","first-page":"771","DOI":"10.4049\/jimmunol.150.3.771","article-title":"Inducible T cell antigen 4-1BB. Analysis of expression and function","volume":"150","year":"1993","journal-title":"J Immunol"},{"key":"2025101313401020000_2025.10.09.681362v1.55","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1997.8016"},{"key":"2025101313401020000_2025.10.09.681362v1.56","first-page":"2022","article-title":"4-1BB: A promising target for cancer immunotherapy","volume":"12","year":"2022","journal-title":"Frontiers in Oncology"},{"issue":"5","key":"2025101313401020000_2025.10.09.681362v1.57","doi-asserted-by":"crossref","first-page":"e64425","DOI":"10.1371\/journal.pone.0064425","article-title":"CD137 Is Induced by the CD40 Signal on Chronic Lymphocytic Leukemia B Cells and Transduces the Survival Signal via NF-\u03baB Activation","volume":"8","year":"2013","journal-title":"PLOS ONE"},{"key":"2025101313401020000_2025.10.09.681362v1.58","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e318268c6ea"},{"issue":"11","key":"2025101313401020000_2025.10.09.681362v1.59","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1080\/10428194.2019.1607330","article-title":"Epstein-Barr virus-encoded LMP1 induces ectopic CD137 expression on Hodgkin and Reed-Sternberg cells via the PI3K-AKT-mTOR pathway","volume":"60","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"2025101313401020000_2025.10.09.681362v1.60","doi-asserted-by":"crossref","first-page":"e112564","DOI":"10.1371\/journal.pone.0112564","article-title":"CD137 expression is induced by Epstein-Barr virus infection through LMP1 in T or NK cells and mediates survival promoting signals","volume":"9","year":"2014","journal-title":"PLoS One"},{"key":"2025101313401020000_2025.10.09.681362v1.61","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/28.20.3918"},{"key":"2025101313401020000_2025.10.09.681362v1.62","doi-asserted-by":"crossref","unstructured":"Huang, H.-H. , et al., TRIM5\u03b1 Promotes Ubiquitination of Rta from Epstein\u2013Barr Virus to Attenuate Lytic Progression. Frontiers in Microbiology, 2017. 7.","DOI":"10.3389\/fmicb.2016.02129"},{"key":"2025101313401020000_2025.10.09.681362v1.63","unstructured":"Information N.C.f.B., PubChem Compound Summary for CID 49857317, Hdac inhibitor CHR-3996. 2024."},{"key":"2025101313401020000_2025.10.09.681362v1.64","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.26.15209"},{"key":"2025101313401020000_2025.10.09.681362v1.65","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02717-07"},{"key":"2025101313401020000_2025.10.09.681362v1.66","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2011.08.013"},{"issue":"12","key":"2025101313401020000_2025.10.09.681362v1.67","first-page":"e1005346","article-title":"Phosphoproteomic Profiling Reveals Epstein-Barr Virus Protein Kinase Integration of DNA Damage Response and Mitotic Signaling","volume":"11","year":"2016","journal-title":"PLOS Pathogens"},{"key":"2025101313401020000_2025.10.09.681362v1.68","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M411405200"},{"key":"2025101313401020000_2025.10.09.681362v1.69","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.04.062"},{"key":"2025101313401020000_2025.10.09.681362v1.70","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.11.071"},{"key":"2025101313401020000_2025.10.09.681362v1.71","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006868"},{"key":"2025101313401020000_2025.10.09.681362v1.72","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1919133117"},{"key":"2025101313401020000_2025.10.09.681362v1.73","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.18845-0"},{"key":"2025101313401020000_2025.10.09.681362v1.74","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00712-10"},{"key":"2025101313401020000_2025.10.09.681362v1.75","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.1.544-549.2004"},{"key":"2025101313401020000_2025.10.09.681362v1.76","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01762-13"},{"issue":"1","key":"2025101313401020000_2025.10.09.681362v1.77","first-page":"P42","article-title":"Signal transducer and activator of transcription 3 (STAT3) controls susceptibility to Epstein-Barr virus reactivation in B cells","volume":"7","year":"2012","journal-title":"Infectious Agents and Cancer"},{"issue":"12","key":"2025101313401020000_2025.10.09.681362v1.78","doi-asserted-by":"crossref","first-page":"5088","DOI":"10.1111\/cas.15152","article-title":"A STING inhibitor suppresses EBV-induced B cell transformation and lymphomagenesis","volume":"112","year":"2021","journal-title":"Cancer Sci"},{"key":"2025101313401020000_2025.10.09.681362v1.79","doi-asserted-by":"crossref","unstructured":"Zhao, Y. and J. Karijolich , Know Thyself: RIG-I-Like Receptor Sensing of DNA Virus Infection. J Virol, 2019. 93(23).","DOI":"10.1128\/JVI.01085-19"},{"issue":"6","key":"2025101313401020000_2025.10.09.681362v1.80","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3390\/microorganisms7060183","article-title":"Epstein\u2013Barr Virus and Innate Immunity: Friends or Foes?","volume":"7","year":"2019","journal-title":"Microorganisms"},{"key":"2025101313401020000_2025.10.09.681362v1.81","doi-asserted-by":"publisher","DOI":"10.1038\/sj.emboj.7601314"},{"issue":"6","key":"2025101313401020000_2025.10.09.681362v1.82","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.3390\/biomedicines10061250","article-title":"NF-\u03baB: A Double-Edged Sword Controlling Inflammation","volume":"10","year":"2022","journal-title":"Biomedicines"},{"issue":"2","key":"2025101313401020000_2025.10.09.681362v1.83","doi-asserted-by":"crossref","first-page":"zcaf017","DOI":"10.1093\/narcan\/zcaf017","article-title":"Leveraging the interconnected unfolded protein response and NLRP3 inflammasome pathways to reactivate Epstein-Barr virus in diffuse large B-cell lymphomas","volume":"7","year":"2025","journal-title":"NAR Cancer"},{"key":"2025101313401020000_2025.10.09.681362v1.84","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2023.05.018"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2025.10.09.681362","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T09:46:21Z","timestamp":1768470381000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2025.10.09.681362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":84,"URL":"https:\/\/doi.org\/10.1101\/2025.10.09.681362","relation":{},"subject":[],"published":{"date-parts":[[2025,10,9]]},"subtype":"preprint"}}